India, June 24 -- British drug major AstraZeneca Plc. (AZN.L,AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed with Daiichi Sankyo Company Limited (DSKYF.PK), for the treatment of adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer or NSCLC.
Following approval in the US, AstraZeneca is required to pay $45 million to Daiichi Sankyo as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication. Sales of Datroway in the US are recognized by Daiichi Sankyo.
Datroway is a specifically engineered TROP2-directed DXd antibody drug conjugate or ADC discovered by Daiichi Sankyo, and being jointly...